## Annotator® - "Tumor Identity Cards (CIT)®" Database

Head :Ayadi Mira, CIT / Recherche

De Reyniès Aurélien , CIT / Recherche Petel Fabien, CIT / Recherche

Last update : 03/12/2014 | Version : 2 | ID : 8214

General	
Identification	
Detailed name	"Tumor Identity Cards (CIT)®" Database
Sign or acronym	Annotator®
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL approval - no. 1381614
General Aspects	
Medical area	Biology Cancer research Immunology
Health determinants	Addictions Genetic Geography Lifestyle and behavior Medicine Occupation
Keywords	genome, methylation patterns, French National League Against Cancer, alterations, chromosomal rearrangement, gene expression, microRNA, cancer cells, personalised medicine, exons
Scientific investigator(s) (Contact)	
Name of the director	Ayadi
Surname	Mira
Address	14 rue Corvisart
Phone	01 53 55 24 00
Email	Mira.Ayadi@ligue-cancer.net

Unit	CIT / Recherche
Organization	Ligue Nationale Contre le Cancer
Name of the director	De Reyniès
Surname	Aurélien
Phone	01 53 55 24 00
Unit	CIT / Recherche
Organization	Ligue Nationale Contre le Cancer
Name of the director	Petel
Surname	Fabien
Address	14 rue Corvisart, 75013 Paris, France
Phone	01 53 55 24 00
Email	Fabien.Petel@ligue-cancer.net
Unit	CIT / Recherche
Organization	Ligue Nationale Contre le Cancer
Organization Collaborations	Ligue Nationale Contre le Cancer
	Ligue Nationale Contre le Cancer Yes
Collaborations Participation in projects,	
Collaborations Participation in projects, networks and consortia	Yes More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international
Collaborations Participation in projects, networks and consortia Details	Yes More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals. The CIT Programme has created a national network
Collaborations Participation in projects, networks and consortia Details Others	Yes More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals. The CIT Programme has created a national network
Collaborations Participation in projects, networks and consortia Details Others Funding	Yes More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals. The CIT Programme has created a national network of clinicians, researchers and institutions
Collaborations Participation in projects, networks and consortia Details Others Funding Funding status	Yes More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals. The CIT Programme has created a national network of clinicians, researchers and institutions Private CIT is a national cancer genomics programme that is established, funded and managed by the French

responsible	against Cancer)
Organisation status	Private
Presence of scientific or steering committees	Yes
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is is made on the basis of:	Medication(s) taken Another treatment or procedure
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	The CIT programme relies on a national network of researchers and clinicians, and on a set of technological platforms (molecular biology 'omics').
Database objective	
Main objective	To comprehensively characterise and integrate cellular signals and associate them with patient history and treatments. Biological events can be genome alterations, mutations, chromosomal rearrangements, gene and miRNA expressions, methylation patterns, exon variations, etc As such, CIT is developing an integrated view of how cancer cells develop and function. This work forms the basis of personalised medicine that is adapted to the genomic characteristics of each tumour. CIT may then identify molecular signatures of patients who are more likely to respond well to a treatment, or whose cancer is deemed more aggressive, therefore helping MDs to choose the best treatment and care.
Inclusion criteria	Inclusion criteria depends on each cancer-specific project inside the CIT Programme, and relate to the biological and clinical questions raised by the PIs. Studies may involve patient monitoring within a

hospital setting, or patients previously included in a prospective clinical study. Informed patient consent is obtained beforehand. Studied diseases may be paediatric tumours or adult cancers, and may apply to solid tumours or hematologic malignancies or lymphoma. Secure data access is restricted to the researchers involved in the Programme.

## Population type

Age	Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	France mainly; some european cohorts
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2000
Date of last collection (YYYY or MM/YYYY)	2015
Size of the database	
Size of the database (number of individuals)	[10 000-20 000[ individuals
Details of the number of individuals	Mid-2015, the CIT programme's database was containing histological, clinical and biological information from 13,000 anonymized patients, all types of cancer included, and 19,000 'omics' experiments (SNP/Expression/miRNA/Exon/Methylation; microarray or NGS).

Data	
Database activity	Current data collection
Type of data collected	Clinical data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures
Details of collected clinical data	diagnosis, stage, grade, pathological conditions, side-effects
Paraclinical data (detail)	Protein expression; gene mutation identification (ABCB1, AKT1, APC, BCL2, BRAF, BRCA1 / 2, CCND1, CDKN2A, CTNNB1, EGFR, ERBB2, etc.), known translocations (1p/19q) or alterations (microsatellite allelic loss, etc.).
Biological data (detail)	Presence of adenomas. Cellular morphology, differentiation, fibrosis, mitosis and necrosis. Percentage of tumour cells. Hyperplasia. AFP. Albumin. ALP. B2 microglobulin. Bilirubin. CEA. LDH. Metanephrine. PSA. Sedimentation rate. WBC.
Presence of a biobank	Yes
Contents of biobank	Whole blood Blood cells isolated Tissues Cell lines DNA DNAc/RNAm Others
Details of biobank content	Tumour samples.
Health parameters studied	Health event/morbidity Health event/mortality Others
Other (detail)	relapse, metastasis, second cancer
Procedures	
Classifications used	ICD
Quality procedure(s) used	external ontologies and internal semi-structured vocabulary
Participant monitoring	Yes
Links to administrative sources	No

Promotion and access	
Promotion	
Link to the document	http://cit.ligue-cancer.net/?page_id=59
Description	List of publications
Access	
Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Secure data access is restricted to the researchers involved in the CIT Programme
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only